• Amphastar Pharmaceuticals Inc AMPH.OQ reported quarterly adjusted earnings of 74 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of $1.04. The mean expectation of six analysts for the quarter was for earnings of 69 cents per share. Wall Street expected results to range from 58 cents to 76 cents per share.

• Revenue fell 0.8% to $170.53 million from a year ago; analysts expected $171.21 million.

• Amphastar Pharmaceuticals Inc's reported EPS for the quarter was 51 cents​.

• The company reported quarterly net income of $25.29 million.

• Amphastar Pharmaceuticals Inc shares had fallen by 15.7% this quarter and lost 34.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 21.8% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Amphastar Pharmaceuticals Inc is $32.50

This summary was machine generated from LSEG data May 8 at 10:58 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)